KOD Kodiak Pharma: EV/EBITDA Multiple

Corporate company logo of Kodiak Pharma (KOD)

Kodiak Sciences Inc. (KOD) is deploying capital toward ophthalmology research without current sales. Meanwhile, the company's biopolymer developments reduce the number of injections, simplifying the treatment of blindness. Past trial failures create risks despite cost optimization. The EV/EBITDA valuation trend demonstrates the asset's volatility, where 0.00 records a new level mark.

KOD Kodiak Pharma: Total Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/16/2026

KOD (Kodiak Sciences): analytical breakdowns and indicator data

- stock price and consensus target price:
Fundamental company valuation:kodiak.com KOD
Original product of kodiak.com

Developing the unique ABC biopolymer platform for retinal therapy requires colossal capital expenditures, making the business value dependent on debt load and operational efficiency. By analyzing the EV/EBITDA history of Kodiak Sciences Inc. (KOD), an investor can see the ratio of total enterprise value to earnings before interest, taxes, depreciation, and amortization, which allows for an assessment of the company's real value considering its loans and technological barriers.

Analysis of competing companies

Alcon Inc - Enterprise Value to EBITDA Ratio|Bausch + Lomb (BLCO) - Company Value to EBITDA|GKOS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA Apellis|BLTE: EV/EBITDA Multiple|Company Value to EBITDA Ocular Pharma (OCUL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization harrowinc.com|Viridian Therapeutics, Inc. (VRDN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LENZ Therapeutics (LENZ)|EV/EBITDA Multiple Oculis AG (OCS)|eyepointpharma.com - Enterprise Value to EBITDA Ratio|Aldeyra - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|KALA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Opus Genetics, Inc. IRD|okyopharma.com (OKYO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Adverum (ADVM)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization outlooktherapeutics.com|CLSD: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio NBY (NovaBay Pharmaceuticals)|KPRX (Kiora Pharmaceuticals Inc.) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALIM (Alimera Sciences Inc)|Total Company Value to Operating Income Before Depreciation Ratio Eyenovia Corp (EYEN)|GHSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Ocuphire Pharma, Inc.|opthea.com (OPT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization